Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)
Launched by BETH ISRAEL DEACONESS MEDICAL CENTER · Mar 24, 2020
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two treatments, Cognitive Enhancement Therapy (CET) and Social Skills Training (SST), to see which one helps people with serious mental illnesses like schizophrenia improve their ability to function in the community. Both treatments have shown to be effective, but the researchers want to find out if they work better for different people, especially considering their age and thinking abilities. The study involves different mental health service centers, where each center will provide either CET or SST to participants.
To join the trial, individuals need to be between 18 and 65 years old and have a diagnosed mental health condition like schizophrenia. They must also have an estimated IQ above 70. However, those with certain brain conditions or intellectual disabilities, or who have participated in either treatment in the past year, won't be eligible. Participants can expect to receive one of the two therapies, and their progress will be monitored to see how well they are doing in everyday life. This research aims to help improve treatment options for people with serious mental illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age 18 to 65;
- • 2. DSM-5 diagnosis of schizophrenia or schizoaffective or schizophreniform disorder (confirmed via the MINI diagnostic interview);
- • 3. estimated IQ of \> 70 (established via WTAR).
- Exclusion Criteria:
- • 1. the presence of a current organic brain syndrome;
- • 2. intellectual disability (DSM-5);
- • 3. participation in either CET or SST within the prior year.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center (BIDMC) is a leading academic medical center located in Boston, Massachusetts, affiliated with Harvard Medical School. Renowned for its commitment to cutting-edge research and innovation in healthcare, BIDMC fosters a collaborative environment that integrates patient care, education, and scientific investigation. The center actively sponsors clinical trials across a variety of disciplines, aiming to advance medical knowledge and improve patient outcomes. With a focus on translational medicine, BIDMC's research initiatives engage multidisciplinary teams to address complex health challenges and translate findings into effective therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Portland, Maine, United States
Boston, Massachusetts, United States
Hartford, Connecticut, United States
Worcester, Massachusetts, United States
Patients applied
Trial Officials
Matcheri S Keshavan, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Russell K Schutt, PhD
Principal Investigator
Beth Israel Deaconess Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials